S&P 500   3,775.72 (-1.92%)
DOW   30,450.06 (-1.57%)
QQQ   323.97 (-1.41%)
AAPL   143.78 (+0.43%)
MSFT   235.11 (+1.20%)
FB   275.68 (-2.26%)
GOOGL   1,842.76 (-3.42%)
AMZN   3,282.84 (-1.30%)
TSLA   883.61 (+0.06%)
NVDA   522.40 (-2.79%)
BABA   262.86 (-1.15%)
CGC   38.27 (+7.74%)
GE   10.83 (-4.07%)
MU   76.65 (-3.60%)
AMD   90.93 (-3.99%)
NIO   58.06 (-3.73%)
T   29.26 (-1.65%)
F   10.86 (-2.95%)
ACB   11.54 (+8.15%)
BA   194.09 (-3.94%)
DIS   163.91 (-3.33%)
NFLX   537.33 (-4.38%)
GILD   65.67 (-1.54%)
S&P 500   3,775.72 (-1.92%)
DOW   30,450.06 (-1.57%)
QQQ   323.97 (-1.41%)
AAPL   143.78 (+0.43%)
MSFT   235.11 (+1.20%)
FB   275.68 (-2.26%)
GOOGL   1,842.76 (-3.42%)
AMZN   3,282.84 (-1.30%)
TSLA   883.61 (+0.06%)
NVDA   522.40 (-2.79%)
BABA   262.86 (-1.15%)
CGC   38.27 (+7.74%)
GE   10.83 (-4.07%)
MU   76.65 (-3.60%)
AMD   90.93 (-3.99%)
NIO   58.06 (-3.73%)
T   29.26 (-1.65%)
F   10.86 (-2.95%)
ACB   11.54 (+8.15%)
BA   194.09 (-3.94%)
DIS   163.91 (-3.33%)
NFLX   537.33 (-4.38%)
GILD   65.67 (-1.54%)
S&P 500   3,775.72 (-1.92%)
DOW   30,450.06 (-1.57%)
QQQ   323.97 (-1.41%)
AAPL   143.78 (+0.43%)
MSFT   235.11 (+1.20%)
FB   275.68 (-2.26%)
GOOGL   1,842.76 (-3.42%)
AMZN   3,282.84 (-1.30%)
TSLA   883.61 (+0.06%)
NVDA   522.40 (-2.79%)
BABA   262.86 (-1.15%)
CGC   38.27 (+7.74%)
GE   10.83 (-4.07%)
MU   76.65 (-3.60%)
AMD   90.93 (-3.99%)
NIO   58.06 (-3.73%)
T   29.26 (-1.65%)
F   10.86 (-2.95%)
ACB   11.54 (+8.15%)
BA   194.09 (-3.94%)
DIS   163.91 (-3.33%)
NFLX   537.33 (-4.38%)
GILD   65.67 (-1.54%)
S&P 500   3,775.72 (-1.92%)
DOW   30,450.06 (-1.57%)
QQQ   323.97 (-1.41%)
AAPL   143.78 (+0.43%)
MSFT   235.11 (+1.20%)
FB   275.68 (-2.26%)
GOOGL   1,842.76 (-3.42%)
AMZN   3,282.84 (-1.30%)
TSLA   883.61 (+0.06%)
NVDA   522.40 (-2.79%)
BABA   262.86 (-1.15%)
CGC   38.27 (+7.74%)
GE   10.83 (-4.07%)
MU   76.65 (-3.60%)
AMD   90.93 (-3.99%)
NIO   58.06 (-3.73%)
T   29.26 (-1.65%)
F   10.86 (-2.95%)
ACB   11.54 (+8.15%)
BA   194.09 (-3.94%)
DIS   163.91 (-3.33%)
NFLX   537.33 (-4.38%)
GILD   65.67 (-1.54%)
Log in
NASDAQ:CLLS

Cellectis Stock Forecast, Price & News

$29.02
-1.09 (-3.62 %)
(As of 01/27/2021 02:09 PM ET)
Add
Compare
Today's Range
$27.45
Now: $29.02
$29.61
50-Day Range
$25.86
MA: $29.40
$33.25
52-Week Range
$7.32
Now: $29.02
$34.71
Volume27,516 shs
Average Volume409,554 shs
Market Capitalization$1.23 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.59
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); ALLO-501 to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; UCART123 for the treatment of acute myeloid leukemia (AML); and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics. The company was founded in 1999 and is headquartered in Paris, France.
Cellectis logo

MarketRank

Overall MarketRank

0.83 out of 5 stars

Medical Sector

1102nd out of 1,925 stocks

Biological Products, Except Diagnostic Industry

138th out of 177 stocks

Analyst Opinion: 1.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CLLS
CUSIPN/A
Phone33-1-81-69-16-00
Employees253
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.99 million
Book Value$8.37 per share

Profitability

Net Income$-102,090,000.00
Net Margins-110.52%

Miscellaneous

Market Cap$1.23 billion
Next Earnings Date3/3/2021 (Estimated)
OptionableOptionable
$29.02
-1.09 (-3.62 %)
(As of 01/27/2021 02:09 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CLLS News and Ratings via Email

Sign-up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cellectis (NASDAQ:CLLS) Frequently Asked Questions

How has Cellectis' stock been impacted by COVID-19?

Cellectis' stock was trading at $11.43 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CLLS stock has increased by 153.9% and is now trading at $29.02.
View which stocks have been most impacted by COVID-19
.

Is Cellectis a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last twelve months. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cellectis stock.
View analyst ratings for Cellectis
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Cellectis?

Wall Street analysts have given Cellectis a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cellectis wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is André Choulika's approval rating as Cellectis' CEO?

4 employees have rated Cellectis CEO André Choulika on Glassdoor.com. André Choulika has an approval rating of 100% among Cellectis' employees. This puts André Choulika in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When is Cellectis' next earnings date?

Cellectis is scheduled to release its next quarterly earnings announcement on Wednesday, March 3rd 2021.
View our earnings forecast for Cellectis
.

How were Cellectis' earnings last quarter?

Cellectis S.A. (NASDAQ:CLLS) released its earnings results on Thursday, November, 5th. The biotechnology company reported ($0.71) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.69) by $0.02. The biotechnology company earned $9.24 million during the quarter, compared to the consensus estimate of $2.25 million. Cellectis had a negative net margin of 110.52% and a negative trailing twelve-month return on equity of 23.56%.
View Cellectis' earnings history
.

What price target have analysts set for CLLS?

6 brokers have issued 12 month price objectives for Cellectis' shares. Their forecasts range from $11.00 to $39.00. On average, they expect Cellectis' stock price to reach $27.20 in the next year. This suggests that the stock has a possible downside of 6.3%.
View analysts' price targets for Cellectis
or view Wall Street analyst' top-rated stocks.

Who are some of Cellectis' key competitors?

What other stocks do shareholders of Cellectis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectis investors own include Gilead Sciences (gild), Calyxt (CLXT), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Intel (INTC) and Sorrento Therapeutics (SRNE).

Who are Cellectis' key executives?

Cellectis' management team includes the following people:
  • Dr. André Choulika, Co-Founder, CEO & Director (Age 56, Pay $1M)
  • Dr. David J. D. Sourdive, Co-Founder, Exec. VP of Strategic Initiatives & Director (Age 54, Pay $452.66k)
  • Mr. Eric Dutang, Chief Financial Officer (Age 47)
  • Mr. Jean Charles Epinat, Chief Technological Officer
  • Mr. Stephan Reynier, Chief Regulatory & Compliance Officer (Age 52)
  • Ms. Marie-Bleuenn Terrier, Gen. Counsel (Age 39)
  • Ms. Jennifer Moore, Sr. VP of PR
  • Ms. Kyung Nam-Wortman, Exec. VP & Chief HR Officer
  • Dr. Philippe Duchateau Ph.D., Chief Scientific Officer (Age 58)
  • Simon Harnest, Sr. VP of Corp. Strategy & Fin.

When did Cellectis IPO?

(CLLS) raised $129 million in an initial public offering (IPO) on Wednesday, March 25th 2015. The company issued 3,500,000 shares at a price of $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager.

What is Cellectis' stock symbol?

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

Who are Cellectis' major shareholders?

Cellectis' stock is owned by a number of institutional and retail investors. Top institutional investors include Exchange Traded Concepts LLC (0.14%) and OneAscent Financial Services LLC (0.06%).

Which institutional investors are buying Cellectis stock?

CLLS stock was acquired by a variety of institutional investors in the last quarter, including Exchange Traded Concepts LLC, and OneAscent Financial Services LLC.

How do I buy shares of Cellectis?

Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cellectis' stock price today?

One share of CLLS stock can currently be purchased for approximately $29.02.

How big of a company is Cellectis?

Cellectis has a market capitalization of $1.23 billion and generates $22.99 million in revenue each year. The biotechnology company earns $-102,090,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Cellectis employs 253 workers across the globe.

What is Cellectis' official website?

The official website for Cellectis is www.cellectis.com.

How can I contact Cellectis?

Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected]

This page was last updated on 1/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.